Clinical Trials

Ghrelin agonist shows selectivity profile in treating gastrointestinal disorders

Published in Medical Letter on the CDC and FDA, August 14th, 2005

Tranzyme Pharma Inc., a biopharmaceutical company developing small molecule therapeutics for the treatment of gastrointestinal (GI) disorders, announced new efficacy data for TZP-101, the company's lead product for the treatment of post-operative ileus and diabetic gastroparesis.

TZP-101 is a small molecule ghrelin receptor agonist, which has been shown to selectively stimulate motility of the GI tract. In a presentation at the 20th International Symposium on Neurogastroenterology & Motility (Toulouse, France), Tranzyme Pharma presented new in vivo data demonstrating that the potent and selective gastroprokinetic activity of TZP-101 takes place without the release of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-08-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry